Optimizing combination therapies with existing and future CML drugs.
Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed to treat Chromic Myeloid Leukemia (CML). The existence of a triple-cross-resistant mutation, T315I, has been a challenging problem, which can be overcome by finding new inhibitors. Many new compounds active against T315I mutants are now at different stages of development. In this paper we develop an algorithm which can weigh different combination treatment protocols according to their cross-resistance properties, and find the protocols with the highest probability of treatment success. This algorithm also takes into account drug toxicity by minimizing the number of drugs used, and their concentration. Although our methodology is based on a stochastic model of CML microevolution, the algorithm itself does not require measurements of any parameters (such as mutation rates, or division/death rates of cells), and can be used by medical professionals without a mathematical background. For illustration, we apply this algorithm to the mutation data obtained in [1], [2].
Katouli
Allen A
AA
Department of Mathematics, University of California Irvine, Irvine, California, United States of America.
Komarova
Natalia L
NL
D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D008954:Models, Biological; D009154:Mutation; D011336:Probability; D013269:Stochastic Processes; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Curr Top Med Chem. 2008;8(10):905-21
18673174
J Theor Biol. 2006 Apr 7;239(3):351-66
16194548
Blood. 2007 Dec 1;110(12):4055-63
17720881
Math Biosci. 2007 Sep;209(1):292-315
17306310
J Math Biol. 2004 Apr;48(4):375-422
15052504
Math Biosci. 1992 Apr;109(1):85-97
1591451
J Biol Chem. 2008 Jun 27;283(26):18292-302
18434310
Adv Cancer Res. 2004;91:1-30
15327887
Blood. 2007 Jan 15;109(2):500-2
16990603
Leuk Lymphoma. 2004 Nov;45(11):2197-203
15512807
Nature. 2010 Jan 28;463(7280):501-6
20072125
Leuk Res. 2008 Jun;32(6):980-3
18191450
Nat Rev Drug Discov. 2004 Dec;3(12):1001-10
15573099
Cancer Res. 2007 Sep 1;67(17):7987-90
17804707
Lancet Oncol. 2007 Nov;8(11):1018-29
17976612
Chem Biol Drug Des. 2007 Sep;70(3):171-81
17718712
Adv Exp Med Biol. 1988;233:1-4
3066148
Curr Opin Hematol. 2004 Jan;11(1):35-43
14676625
Recent Results Cancer Res. 2010;184:199-214
20072840
J Clin Oncol. 2009 Jan 20;27(3):469-71
19075254
Mol Cancer Ther. 2003 Oct;2(10):1079-84
14578473
Nat Rev Cancer. 2007 May;7(5):345-56
17457302
Math Biosci. 1995 Dec;130(2):151-81
8527869
Blood. 2007 Jan 15;109(2):497-9
16990591
J Mol Med (Berl). 2008 Jan;86(1):17-27
17661001
Mutat Res. 1993 Aug;292(1):17-24
7688093
Cell Biol Toxicol. 1989 Dec;5(4):445-60
2560673
Blood. 2009 Dec 24;114(27):5426-35
19880502
Blood. 2006 Oct 1;108(7):2332-8
16772610
Exp Hematol. 2007 Apr;35(4 Suppl 1):144-54
17379100
Cancer Treat Rep. 1983 Oct;67(10):923-31
6627236
Theor Popul Biol. 2007 Dec;72(4):523-38
17915274
PLoS One. 2009;4(2):e4423
19204794
Cancer Treat Rep. 1985 Oct;69(10):1041-8
2412691
Cancer. 2003 May 1;97(9):2229-35
12712476
Risk Anal. 1988 Sep;8(3):383-92
3201016
Genetics. 1990 Jul;125(3):633-44
2379824
J Clin Oncol. 2003 Apr 15;21(8):1637-47
12668652
Lancet Oncol. 2003 Feb;4(2):75-85
12573349
J Natl Cancer Inst. 1994 Aug 3;86(15):1152-8
8028036
Hematology Am Soc Hematol Educ Program. 2003;:132-52
14633780
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5507-12
18367669
Math Biosci. 2000 Mar;164(1):17-38
10704636
J Natl Cancer Inst. 1981 Jun;66(6):1037-52
6941039
Blood. 2004 Jun 1;103(11):4010-22
14982876
Blood. 1987 Oct;70(4):905-8
3477299
Blood. 2008 Apr 15;111(8):4355-64
18268096
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9714-9
15980154
Bull Math Biol. 2005 May;67(3):563-611
15820743
PLoS One. 2007 Oct 03;2(10):e990
17912367
Cancer Cell. 2002 Aug;2(2):99-102
12204529
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33
526911
Blood. 2007 Oct 1;110(7):2242-9
17496200
Int J Hematol. 2004 Jun;79(5):420-33
15239391
N Engl J Med. 2006 Jun 15;354(24):2531-41
16775234
Clin Cancer Res. 2009 Nov 1;15(21):6694-701
19825950
Leuk Lymphoma. 2008 Apr;49(4):615-9
18398720
Mol Cancer Ther. 2003 Mar;2(3):225-6
12657716
Math Biosci. 1991 Feb;103(1):115-38
1804437
Blood. 2007 Mar 1;109(5):2112-20
17068153
N Engl J Med. 2006 Jun 15;354(24):2542-51
16775235
Leukemia. 2002 Aug;16(8):1402-11
12145676
Bull Math Biol. 1994 Mar;56(2):337-57
8186758
Bull Math Biol. 1986;48(3-4):279-92
3828558
Curr Pharm Des. 2006;12(3):261-71
16454743